Literature DB >> 8097103

P glycoprotein (P-gp) and drug resistance--time for reappraisal?

S B Kaye.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8097103      PMCID： PMC1968337          DOI： 10.1038/bjc.1993.119

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  24 in total

1.  Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer.

Authors:  C J Rodenburg; K Nooter; H Herweijer; C Seynaeve; R Oosterom; G Stoter; J Verweij
Journal:  Ann Oncol       Date:  1991-04       Impact factor: 32.976

2.  Phase I and pharmacokinetic study of rhizoxin.

Authors:  D Bissett; M A Graham; A Setanoians; G A Chadwick; P Wilson; I Koier; R Henrar; G Schwartsmann; J Cassidy; S B Kaye
Journal:  Cancer Res       Date:  1992-05-15       Impact factor: 12.701

3.  P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma.

Authors:  H S Chan; G Haddad; P S Thorner; G DeBoer; Y P Lin; N Ondrusek; H Yeger; V Ling
Journal:  N Engl J Med       Date:  1991-12-05       Impact factor: 91.245

4.  Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis.

Authors:  R S Weinstein; S M Jakate; J M Dominguez; M D Lebovitz; G K Koukoulis; J R Kuszak; L F Klusens; T M Grogan; T J Saclarides; I B Roninson
Journal:  Cancer Res       Date:  1991-05-15       Impact factor: 12.701

5.  Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells.

Authors:  P M Chaudhary; I B Roninson
Journal:  Cell       Date:  1991-07-12       Impact factor: 41.582

6.  Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma.

Authors:  P Verrelle; F Meissonnier; Y Fonck; V Feillel; C Dionet; F Kwiatkowski; R Plagne; J Chassagne
Journal:  J Natl Cancer Inst       Date:  1991-01-16       Impact factor: 13.506

7.  Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas.

Authors:  T A Holzmayer; S Hilsenbeck; D D Von Hoff; I B Roninson
Journal:  J Natl Cancer Inst       Date:  1992-10-07       Impact factor: 13.506

8.  Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON.

Authors:  P Sonneveld; B G Durie; H M Lokhorst; J P Marie; G Solbu; S Suciu; R Zittoun; B Löwenberg; K Nooter
Journal:  Lancet       Date:  1992-08-01       Impact factor: 79.321

9.  P-glycoprotein expression during tumor progression in the rat liver.

Authors:  G Bradley; R Sharma; S Rajalakshmi; V Ling
Journal:  Cancer Res       Date:  1992-10-01       Impact factor: 12.701

10.  Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.

Authors:  B L Lum; S Kaubisch; A M Yahanda; K M Adler; L Jew; M N Ehsan; N A Brophy; J Halsey; M P Gosland; B I Sikic
Journal:  J Clin Oncol       Date:  1992-10       Impact factor: 44.544
View more
  9 in total

1.  Origin of multidrug resistance in cells with and without multidrug resistance genes: chromosome reassortments catalyzed by aneuploidy.

Authors:  P Duesberg; R Stindl; R Hehlmann
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

2.  A new mdr-1 encoded P-170 specific monoclonal antibody: (6/1C) on paraffin wax embedded tissue without pretreatment of sections.

Authors:  E Moran; A Larkin; G Doherty; P Kelehan; S Kennedy; M Clynes
Journal:  J Clin Pathol       Date:  1997-06       Impact factor: 3.411

Review 3.  Classical multidrug resistance in acute myeloid leukaemia.

Authors:  E Paietta
Journal:  Med Oncol       Date:  1997-03       Impact factor: 3.064

4.  Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil, cyclosporine A and SDZ PSC 833 in dependence on extracellular pH.

Authors:  J Zacherl; G Hamilton; T Thalhammer; M Riegler; E P Cosentini; A Ellinger; G Bischof; M Schweitzer; B Teleky; T Koperna
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833.

Authors:  O Gonzalez; T Colombo; M De Fusco; L Imperatori; M Zucchetti; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  Relative cytotoxicities of adriamycin and epirubicin in combination with lonidamine against human bladder cancer cell lines.

Authors:  R J Popert; J R Masters; M Coptcoat; G Zupi
Journal:  Urol Res       Date:  1995

Review 7.  Epirubicin: a review of its intravesical use in superficial bladder cancer.

Authors:  S V Onrust; L R Wiseman; K L Goa
Journal:  Drugs Aging       Date:  1999-10       Impact factor: 4.271

8.  Multidrug resistance phenotype in the RMS-GR human rhabdomyosarcoma cell line obtained after polychemotherapy.

Authors:  J Prados; C Melguizo; J A Marchal; C Vélez; L Alvarez; A Aránega
Journal:  Jpn J Cancer Res       Date:  1999-07

9.  Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia.

Authors:  T Colombo; O Gonzalez Paz; M D'Incalci
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.